Highlights

  • Neuren Pharmaceuticals shares rose 3.77% to AUD 12.78 on 7 May 2026, following the release of Q1 2026 results.
  • Q1 2026 DAYBUE net sales increased 20% year-on-year to US$101 million.
  • Royalty income to Neuren rose 23% to US$10.4 million.
  • Acadia reaffirmed FY2026 DAYBUE sales guidance of US$460 million to US$490 million.
  • DAYBUE STIX recorded more than 250 prescriptions during its limited launch phase.
  • Japan trofinetide trial timeline accelerated, with topline data now expected between September and November 2026.

Neuren Pharmaceuticals Ltd (ASX:NEU) shares moved higher during the afternoon session on 7 May 2026, rising 3.77% to AUD 12.78 after the company released a quarterly update tied to commercial performance of DAYBUE (trofinetide), its partnered Rett syndrome treatment.

The stock has now gained 1.31% over the past year, with investors appearing encouraged by continued sales growth, increasing royalty income and signs of expanding uptake for the newly introduced DAYBUE STIX formulation.

The latest update was linked to financial results released by Neuren’s commercialisation partner, Acadia Pharmaceuticals, which reported another quarter of year-on-year growth for DAYBUE in the United States.

Investor attention also appeared focused on accelerating timelines in Japan, positive reception for DAYBUE STIX and reaffirmed full-year sales guidance from Acadia.

Neuren is an Australian biotechnology company focused on therapies targeting neurological disorders linked to genetic abnormalities and brain injury. The company’s products and pipeline are designed around Insulin-like Growth Factor-1 (IGF-1) pathways, using orally administered peptide analogs.

Its approved therapy DAYBUE is currently licensed globally to Acadia Pharmaceuticals, while Neuren continues developing NNZ-2591 across several neurodevelopmental disorders including Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome.

DAYBUE Sales Cross US$100 Million in Q1 2026

Acadia reported Q1 2026 net sales for DAYBUE of US$101 million, representing a 20% increase compared with Q1 2025.

According to Neuren, this marked the highest year-on-year sales growth rate since the third quarter of 2024.

The update also showed continued progression in DAYBUE sales over recent years. Quarterly sales have expanded from US$76 million in Q1 2024 to US$101 million in Q1 2026, reflecting broader patient uptake and increasing treatment penetration.

Acadia maintained its full-year 2026 DAYBUE net sales guidance at US$460 million to US$490 million, implying continued momentum through the remainder of the year.

For Neuren, these commercial trends translated into higher royalty Revenue.

The company earned royalty income of US$10.4 million during Q1 2026, representing a 23% increase from the prior corresponding period.

Based on Acadia’s guidance range, Neuren stated that anticipated full-year royalty income remains unchanged at between US$50 million and US$54 million. Using assumed exchange rates of 0.70 to 0.72 AUD/USD, this equates to approximately AUD 70 million to AUD 77 million.

The royalty structure includes tiered rates on DAYBUE sales in North America, allowing Neuren to participate directly in ongoing commercial growth.

DAYBUE STIX Launch Draws Early Attention

A major area of investor interest in the latest update appeared to be DAYBUE STIX, the newly launched powder formulation of trofinetide.

The product was introduced on a limited basis in the United States during Q1 2026, initially targeting Rett syndrome Centers of Excellence before becoming broadly available in early April.

According to the update, more than 250 prescriptions for DAYBUE STIX were written during the quarter.

Importantly, around 30% of those prescriptions came from either treatment-naïve patients or patients who had previously discontinued therapy.

Management highlighted favourable early reception from both caregivers and healthcare professionals.

Caregiver satisfaction exceeded 80%, while healthcare professionals reportedly demonstrated strong support for the product during the initial rollout phase.

The STIX formulation may be important commercially because it potentially addresses practical administration challenges for some patients and caregivers, which could support broader adoption over time.

Neuren CEO Jon Pilcher stated that he was encouraged by the initial uptake and enthusiasm surrounding the product following its rollout through Centers of Excellence.

He also pointed to what he described as remaining upside potential in the US market, noting that penetration rates currently sit at around 60% within Centers of Excellence and approximately 28% across the broader community.

Expert Consensus Adds Support to DAYBUE Positioning

Another development highlighted in the update involved a Delphi expert consensus panel recommendation regarding DAYBUE use in Rett syndrome treatment.

According to Neuren, the panel recently recommended DAYBUE as part of the standard of care for eligible Rett syndrome patients.

While the company did not quantify the immediate commercial impact of this recommendation, investors often monitor these developments closely because consensus treatment recommendations can influence physician awareness, prescribing confidence and long-term adoption trends.

The recommendation may also support ongoing integration of DAYBUE into broader clinical treatment pathways over time.

Japan Timeline Accelerates as Global Expansion Continues

Outside the United States, investors also appeared to focus on developments in Japan and Europe.

Neuren stated that enrolment in the ongoing trofinetide clinical trial in Japan had accelerated during the quarter.

As a result, topline data is now expected between September and November 2026, earlier than previous expectations of late 2026 or early 2027.

An accelerated timeline may improve visibility around potential regulatory pathways and future geographic expansion opportunities.

Meanwhile, in Europe, the re-examination process for trofinetide is expected to conclude in June 2026.

The company also noted ongoing growth in Named Patient Supply programs outside the United States.

These programs can provide early access to therapies in certain regions prior to broader commercial approvals and may help build physician familiarity with treatment Options.

Royalty Model Continues to Shape Investor Focus

Unlike fully commercial-stage biotechnology companies that directly market products themselves, Neuren’s Business model is currently strongly linked to royalty flows generated through its licensing Partnership with Acadia.

As a result, investors are closely monitoring commercial sales trends for DAYBUE, as changes in prescription momentum, patient uptake and guidance expectations directly influence Neuren’s royalty Earnings profile.

The latest quarter continued the broader trend of rising royalties.

Royalty income expanded from US$10 million in calendar year 2023 to US$18 million in 2024 and US$37 million in 2025, with current 2026 expectations ranging between US$50 million and US$54 million.

This progression has remained a major driver of market attention surrounding Neuren over the past several reporting periods.

Broader Pipeline Remains Part of the Long-Term Story

Although DAYBUE remains the primary near-term commercial focus, Neuren also continues advancing its broader development pipeline.

Its second drug candidate, NNZ-2591, is currently being evaluated across multiple neurodevelopmental disorders.

The company reported positive Phase 2 clinical trial results in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Neuren is currently conducting the Phase 3 “Koala” clinical trial evaluating NNZ-2591 in children with Phelan-McDermid syndrome, alongside an open-label extension study.

Several NNZ-2591 programs have also received Orphan Drug designation, Fast Track Designation and Rare Pediatric Disease designation from regulators in the United States and Europe.

While the latest share price reaction appeared primarily linked to DAYBUE momentum, investors continue monitoring pipeline progress as part of Neuren’s longer-term growth profile.

What This Means for Investors?

Neuren’s latest update appears to have reinforced investor confidence around the commercial trajectory of DAYBUE and the company’s expanding royalty stream.

The combination of 20% sales growth, higher royalty income, reaffirmed FY2026 guidance and positive early feedback for DAYBUE STIX contributed to the favourable market reaction during the afternoon session on 7 May 2026.

Investors also appeared encouraged by accelerating progress in Japan and the recommendation from the Delphi expert panel supporting DAYBUE as part of standard care for eligible Rett syndrome patients.

At the same time, market attention is likely to remain focused on future penetration rates, broader uptake of DAYBUE STIX and the pace of international expansion.

With royalty revenue continuing to rise and several pipeline programs advancing through development, Neuren remains a closely watched biotechnology stock on the ASX.